Recent Company News

• 04:58 PM ET Apr 23, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:53 AM ET Apr 24, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 01:04 PM ET Apr 29, 2026
  

  Zealand Pharma and Roche to advance petrelintide to Phase 3 trials for chronic weight management (DKK 301.00, 0.00)

• 06:31 AM ET Apr 24, 2026
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Venclyxto ($200.95, 0.00)

• 12:14 AM ET Apr 24, 2026
  

  Roche Holding upgraded to equal-weight from underweight at Morgan Stanley (CHF 324.90, 0.00)

• 11:51 AM ET Apr 23, 2026
  

  Transcript Intelligence: Roche Holding Q1 Sales and Revenue Guidance

• 11:51 AM ET Apr 23, 2026
  

  Transcript Intelligence: Roche Holding Q1 Sales and Revenue Themes

• 11:51 AM ET Apr 23, 2026
  

  Transcript Intelligence: Roche Holding Q1 Sales and Revenue Q&A